FDA slaps a hold on KalVis­ta's PhII study of an HAE drug, rais­ing a red flag on pre­clin­i­cal re­sults

Investors on board for KalVista’s roller coaster ride of stock swings are in for some new drama. Two months after the biotech reported positive Phase II results for its lead drug designed to prevent the effects of the rare genetic disorder hereditary angioedema, the FDA has slapped a hold on their Phase II study of their oral drug to prevent HAE.